Cantor Fitzgerald Issues Negative Forecast for FULC Earnings
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) – Stock analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Fulcrum Therapeutics in a research note issued on Thursday, October 30th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($1.19) per share for the year, down from their previous […]
4 Nov 01:46 · The Cerbat Gem